Randomised controlled trials (RCTs) of manidipine versus amlodipine in patients with hypertension were eligible for inclusion. Trials had to last at least one month and provide assessments of systolic and diastolic blood pressure reduction, global side-effects and ankle oedema using validated techniques.
The included trials studied 10mg to 20mg manidipine versus 5mg to 10mg amlodipine in patients with hypertension. Patient ages, where reported, ranged from 35 to 70 years. Trial duration ranged from 12 to 48 weeks. Loss to follow-up varied from 1.56% to 26%.
Two reviewers performed study selection.